PubMed:8752841 JSONTXT

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":374,"end":377},"obj":"gene:4218"},{"id":"T1","span":{"begin":189,"end":197},"obj":"disease:C0025202"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100.\nAnti-melanoma cytolytic T-lymphocyte (CTL) clones were derived from peripheral blood lymphocytes of HLA-A2 melanoma patient LB265 after stimulation with the autologous tumor cell line LB265-MEL, which showed high expression of melanocyte-lineage specific genes. Of 55 CTL clones, 46 recognized HLA-A2-restricted antigens. These 46 CTL clones were studied for their ability to specifically release tumor necrosis factor in the presence of COS cells cotransfected with the HLA-A2 gene and the cDNA of either tyrosinase, Melan-A/MART1, Pmel17/gpl00, gp75/TRP1, or MSH receptor. Six CTL clones recognized the Melan-A/MART1 antigen, whereas the remaining 40 CTL clones recognized a Pmel17/gp100 antigen. These 40 anti-PmelI7/gpl00 CTL clones were all able to lyse T2 cells pulsed with the antigenic peptide YLEPGPVTA, as previously reported. The T-cell receptor beta chain hypervariable region was sequenced and found to be identical in the 15 CTL clones analyzed. Taken together, these data show a high frequency of Pmell7/gp100-specific T cells in autologous antitumor CTL clones derived from peripheral blood of a melanoma patient."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"8752841-1#190#193#gene4218","span":{"begin":374,"end":377},"obj":"gene4218"},{"id":"8752841-1#5#13#diseaseC0025202","span":{"begin":189,"end":197},"obj":"diseaseC0025202"},{"id":"8752841-1#107#115#diseaseC0025202","span":{"begin":291,"end":299},"obj":"diseaseC0025202"},{"id":"8752841-7#59#64#gene6490","span":{"begin":1203,"end":1208},"obj":"gene6490"},{"id":"8752841-7#152#160#diseaseC0025202","span":{"begin":1296,"end":1304},"obj":"diseaseC0025202"}],"relations":[{"id":"190#193#gene42185#13#diseaseC0025202","pred":"associated_with","subj":"8752841-1#190#193#gene4218","obj":"8752841-1#5#13#diseaseC0025202"},{"id":"190#193#gene4218107#115#diseaseC0025202","pred":"associated_with","subj":"8752841-1#190#193#gene4218","obj":"8752841-1#107#115#diseaseC0025202"},{"id":"59#64#gene6490152#160#diseaseC0025202","pred":"associated_with","subj":"8752841-7#59#64#gene6490","obj":"8752841-7#152#160#diseaseC0025202"}],"text":"The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100.\nAnti-melanoma cytolytic T-lymphocyte (CTL) clones were derived from peripheral blood lymphocytes of HLA-A2 melanoma patient LB265 after stimulation with the autologous tumor cell line LB265-MEL, which showed high expression of melanocyte-lineage specific genes. Of 55 CTL clones, 46 recognized HLA-A2-restricted antigens. These 46 CTL clones were studied for their ability to specifically release tumor necrosis factor in the presence of COS cells cotransfected with the HLA-A2 gene and the cDNA of either tyrosinase, Melan-A/MART1, Pmel17/gpl00, gp75/TRP1, or MSH receptor. Six CTL clones recognized the Melan-A/MART1 antigen, whereas the remaining 40 CTL clones recognized a Pmel17/gp100 antigen. These 40 anti-PmelI7/gpl00 CTL clones were all able to lyse T2 cells pulsed with the antigenic peptide YLEPGPVTA, as previously reported. The T-cell receptor beta chain hypervariable region was sequenced and found to be identical in the 15 CTL clones analyzed. Taken together, these data show a high frequency of Pmell7/gp100-specific T cells in autologous antitumor CTL clones derived from peripheral blood of a melanoma patient."}